id: 822, Created by Stan Vick, Scout
Alexion (ALXN) $125M Shareholder Settlement
How it works?
- Company agreed to pay compensation to its investors, to avoid further litigation
- We help you to prepare documents and file for compensation
30 Jan 2014Class period Start
26 May 2017Class period End
Alexion (ALXN) agreed to settle a $125 million with shareholders to end claims that the $ALXN caused a double-digit plunge in stock price after its allegedly illegal sales strategy came to light.
Failure to Disclose,
Payout per Share
17 November 2016
Boston Retirement System, David A. Slossberg, Jeffrey P. Nichols
Labaton Sucharow LLP, Motley Rice LLC, Sturman LLC, Risch Pisca LLC
Leonard Bell, David L. Hallal, Vikas Sinha
Hon. Alvin W. Thompson
Settlement agreement date
Trades matching type
+$125,000,000Total Settlement Amount
16 September 2023
- Alexion shareholders asked approval from a federal judge in Connecticut for a $125 million settlement.
- This deal aims to resolve allegations that $ALXN allegedly illegal sales strategy led to a significant drop in stock price.
18 September 2023
$ALXN case-related News:
In a New York federal court, a former vice president of Alexion Pharmaceuticals Inc. entered a guilty plea for informing a childhood friend about the $ALXN $1.4 billion acquisition of another biotech firm in 2020.